Hingham, Massachusetts-based Microbot develops the Liberty single-use endovascular robotic surgical system. It designed Liberty for use in neurovascular, cardiovascular and peripheral vascular procedures. The system includes a compact design and remote operating capabilities to reduce radiation exposure and physical strain on physicians.
Key opinion leaders (KOLs) at a New York-based research lab conducted the pre-clinical study. A team of leading interventional radiologists used the system to perform dozens of catheterizations. That includes using the system’s remote operating capabilities on pre-determined vascular targets. Microbot Medical reported a 100% success rate in reaching the intended target with no observable on-site complications.
It also marked the first study allowing participants of leading organizations in the medical industry to join, the company said. Similar to previous studies, it produced positive real-time user feedback. Points of note included intuitiveness, ease of setup and use, plus value added by the remote capabilities.
Microbot said the study also produced valuable input from participants aligning with the value proposition it expects Liberty to bring to market.
In a news release, Hal Gadot, Microbot CEO, said:
“We continue to expand our close relationships with international KOLs and, for the first time, we incorporated executives from the medical industry. We believe that our Liberty robotic surgical system has the potential to benefit patients, physicians and commercial organizations from the medical field as we continue to advance in the regulatory process with the FDA and other regions across the world. Following several successful studies in Europe, and now in the US, the support and endorsement we receive has great value for our future commercial plans.”
